Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up

Nadine Abdallah,Thomas E. Witzig,Shaji K. Kumar,Martha Q. Lacy,Suzanne R. Hayman,Angela Dispenzieri,Vivek Roy,Morie A. Gertz,P. Leif Bergsagel,S. Vincent Rajkumar

DOI: https://doi.org/10.1038/s41375-024-02192-z

2024-02-29

Leukemia

Abstract:Smoldering multiple myeloma (SMM) is an asymptomatic phase of multiple myeloma (MM) first described in 1980 [1]. It is associated with a yearly risk of progression to MM of approximately 10% in the first 5 years, 3% in the following 5 years, and 1% thereafter [2]. While a watch-and-wait strategy has traditionally been the standard approach for SMM, the notion of early intervention has been under investigation for over three decades [3, 4]. The earliest studies using melphalan in combination with steroids did not demonstrate benefit in terms of response or overall survival (OS) [3, 4]. Subsequently, the use of bisphosphonates was associated with reduction in skeletal-related events without improvement in progression-free survival (PFS) or OS [5]. Upon emergence of evidence for thalidomide activity in MM [6], our group conducted a phase II study of thalidomide in SMM, showing activity in this setting [7]. This was the basis of a phase III randomized trial in 2003, which compared thalidomide (Thal) plus zoledronic acid (ZLD) to ZLD in patients with SMM. In 2013, initial results were published after 6 years of follow-up: patients in the Thal+ZLD arm had longer time-to-progression (TTP) (2.4 vs. 1.2 years, P = 0.02) and 1-year PFS (86% vs. 55%, P = 0.005) compared to the ZLD arm, with progression defined according to the International Myeloma Working Group (IMWG) response criteria [8]. Thal+ZLD was also associated with longer TTP and PFS when progression was defined as "CRAB" features, but these results were not statistically significant [9]. The approval of lenalidomide, which is associated with lower neurotoxicity compared to thalidomide, and emergence of SMM risk stratification systems [10,11,12], shaped the design of subsequent studies, which used lenalidomide-based interventions targeting intermediate- and high-risk SMM patients. In the QuiRedex trial, lenalidomide plus dexamethasone combination was associated with longer TTP and OS compared to active surveillance in high-risk SMM [13]. In the ECOG-ACRIN trial, lenalidomide was associated with improvement in PFS, but not OS, in intermediate- or high-risk patients after a follow-up of 35 months [14]. Given the short follow-up, it remains unclear whether early intervention offers a survival advantage. Thus, we performed an updated analysis of the Thal+ZLD vs. ZLD trial to evaluate OS after approximately 18 years of follow-up. We also evaluated TTP to MM and myeloma-free survival among all patients and in the different risk groups. This was a randomized phase III clinical trial (NCT00432458) which enrolled patients ≥ 18 years with a new diagnosis of SMM who had measurable disease. The study design has been previously described [9]. Patients with small asymptomatic lytic lesions on plain skeletal survey radiographs were eligible. Based on the initial protocol, ZLD 4 mg was administered every 28 days; the dosing was later changed to every 3 months for the first year, then yearly, to mitigate the risk of osteonecrosis of the jaw. Patients in the Thal+ZLD arm also received Thal 200 mg/day. There was no crossover between the arms. The study enrolled patients at Mayo Clinic and Memorial Sloan Kettering, but this analysis only included Mayo Clinic patients.

oncology,hematology